PTPN11 hypomethylation is associated with gastric cancer progression

Xu,Lele; Zhou,Cong; Pan,Ranran; Tang,Junjian; Wang,Jinzhi; Li,Bin; Huang,Tianyi; Duan,Shiwei; Xu,Chunfang

doi:10.3892/ol.2020.11250

PTPN11 hypomethylation is associated with gastric cancer progression

Authors:
- Lele Xu
- Cong Zhou
- Ranran Pan
- Junjian Tang
- Jinzhi Wang
- Bin Li
- Tianyi Huang
- Shiwei Duan
- Chunfang Xu
View Affiliations

Affiliations: Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215200, P.R. China, Medical Genetics Center, School of Medicine, Ningbo University, Ningbo, Zhejiang 315211, P.R. China, Department of Vascular Surgery, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214000, P.R. China, Department of Cell Biology, School of Medicine, Soochow University, Suzhou, Jiangsu 215007, P.R. China
Published online on: January 7, 2020 https://doi.org/10.3892/ol.2020.11250
Pages: 1693-1700
Copyright: © Xu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Protein tyrosine phosphatase non‑receptor type 11 (PTPN11) encodes the tyrosine phosphatase SHP‑2 that is overexpressed in gastric cancer (GC). In the present study, the association of PTPN11 methylation levels with the incidence of GC and its correlation with SHP‑2 overexpression were investigated. The methylation levels of PTPN11 in tumor and adjacent normal tissues of 112 GC patients were assessed by quantitative methylation specific PCR (qMSP). The Cancer Genome Atlas (TCGA) public database was used to analyze the association between PTPN11 methylation and PTPN11 expression. Survival analyses were conducted in order to evaluate the prognostic value of PTPN11 methylation for GC. The results of the qMSP analysis indicated that the methylation levels of PTPN11 in GC tumor tissues were significantly decreased compared with those noted in the normal adjacent tissues (mean with standard deviation: 40.91±26.33 vs. 51.99±37.37, P=0.007). An inverse correlation between PTPN11 methylation levels and PTPN11 mRNA expression levels (P=4x10‑6, r=‑0.237) was noted. Subgroup analyses indicated that the association of PTPN11 hypomethylation with the incidence of GC was specific to male subjects (P=0.015), heavy drinking patients (P=0.019), patients with poor tumor differentiation (P=0.010) and patients with tumor node and metastasis (TNM) stage III+IV (P=0.008). Kaplan‑Meier analyses and log‑rank test suggested that PTPN11 hypomethylation was not associated with GC patient overall survival (P=0.605) and recurrence (P=0.485), although it could predict the recurrence of GC patients up to and including 60 years (≤60, P=0.049). The results indicated that PTPN11 levels were hypomethylated in GC patients. TCGA data analysis suggested that PTPN11 hypomethylation could cause an upregulation in the transcription levels of PTPN11. Although, this may explain the pattern of SHP‑2 overexpression in GC, additional studies are required to verify this hypothesis. The association of PTPN11 hypomethylation with GC incidence may be specific to male patients, heavy drinking patients, patients with poor tumor differentiation and patients with TNM stage of III+IV. PTPN11 hypomethylation can be considered a biomarker for the recurrence of GC patients with an age of 60 years or lower.

View Figures

View References

1	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
2	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
3	Yamazaki S, Yamakawa A, Ito Y, Ohtani M, Higashi H, Hatakeyama M and Azuma T: The CagA protein of Helicobacter pylori is translocated into epithelial cells and binds to SHP-2 in human gastric mucosa. J Infect Dis. 187:334–337. 2003. View Article : Google Scholar : PubMed/NCBI
4	Zhang J, Zhang F and Niu R: Functions of Shp2 in cancer. J Cell Mol Med. 19:2075–2083. 2015. View Article : Google Scholar : PubMed/NCBI
5	Inoue K: Gastric cancer risk classification (ABC classification). Nihon Rinsho. 71:1472–1478. 2013.(In Japanese). PubMed/NCBI
6	Hatakeyama M: H. pylori oncoprotein CagA and gastric cancer. Nihon Rinsho. 70:1699–1704. 2012.(In Japanese). PubMed/NCBI
7	Hatakeyama M: Deregulation of SHP-2 tyrosine phosphatase by the Helicobacter pylori virulence factor CagA. Keio J Med. 51 (Suppl 2):S26–S32. 2002. View Article : Google Scholar
8	Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N and Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 345:784–789. 2001. View Article : Google Scholar : PubMed/NCBI
9	Müller PJ, Rigbolt KT, Paterok D, Piehler J, Vanselow J, Lasonder E, Andersen JS, Schaper F and Sobota RM: Protein tyrosine phosphatase SHP2/PTPN11 mistargeting as a consequence of SH2-domain point mutations associated with Noonan Syndrome and leukemia. J Proteomics. 84:132–147. 2013. View Article : Google Scholar : PubMed/NCBI
10	Mutesa L, Pierquin G, Janin N, Segers K, Thomée C, Provenzi M and Bours V: Germline PTPN11 missense mutation in a case of Noonan syndrome associated with mediastinal and retroperitoneal neuroblastic tumors. Cancer Genet Cytogenet. 182:40–42. 2008. View Article : Google Scholar : PubMed/NCBI
11	Lee KA, Williams B, Roza K, Ferguson H, David K, Eddleman K, Stone J, Edelmann L, Richard G, Gelb BD and Kornreich R: PTPN11 analysis for the prenatal diagnosis of Noonan syndrome in fetuses with abnormal ultrasound findings. Clin Genet. 75:190–194. 2009. View Article : Google Scholar : PubMed/NCBI
12	Motegi S, Yokoyama Y, Ogino S, Yamada K, Uchiyama A, Perera B, Takeuchi Y, Ohnishi H and Ishikawa O: Pathogenesis of multiple lentigines in LEOPARD syndrome with PTPN11 gene mutation. Acta Derm Venereol. 95:978–984. 2015. View Article : Google Scholar : PubMed/NCBI
13	Tartaglia M, Niemeyer CM, Shannon KM and Loh ML: SHP-2 and myeloid malignancies. Curr Opin Hematol. 11:44–50. 2004. View Article : Google Scholar : PubMed/NCBI
14	Ibáñez M, Carbonell-Caballero J, García-Alonso L, Such E, Jiménez-Almazán J, Vidal E, Barragán E, López-Pavía M, LLop M, Martín I, et al: The mutational landscape of acute promyelocytic leukemia reveals an interacting network of co-occurrences and recurrent mutations. PLoS One. 11:e01483462016. View Article : Google Scholar : PubMed/NCBI
15	Chen L, Chen W, Mysliwski M, Serio J, Ropa J, Abulwerdi FA, Chan RJ, Patel JP, Tallman MS, Paietta E, et al: Mutated Ptpn11 alters leukemic stem cell frequency and reduces the sensitivity of acute myeloid leukemia cells to Mcl1 inhibition. Leukemia. 29:1290–1300. 2015. View Article : Google Scholar : PubMed/NCBI
16	Yuan L, Lu L, Yang Y, Sun H, Chen X, Huang Y, Wang X, Zou L and Bao L: Genetic mutational profiling analysis of T cell acute lymphoblastic leukemia reveal mutant FBXW7 as a prognostic indicator for inferior survival. Ann Hematol. 94:1817–1828. 2015. View Article : Google Scholar : PubMed/NCBI
17	Yang WY, Chen XJ, Wang SC, Guo Y, Liu TF, Chang LX, Liu F and Zhu XF: Gene mutations and clinical characteristics in children with juvenile myelomonocytic leukemia. Zhongguo Dang Dai Er Ke Za Zhi. 17:1–5. 2015.(In Chinese). PubMed/NCBI
18	Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, Carter SL, Cibulskis K, Hanna M, Kiezun A, et al: The genetic landscape of high-risk neuroblastoma. Nat Genet. 45:279–284. 2013. View Article : Google Scholar : PubMed/NCBI
19	Obasaju P, Brondon J, Mir S, Fordham LA, Lee S and Blatt J: Somatic PTPN11 mutation in a child with neuroblastoma and protein losing enteropathy. J Pediatr Hematol Oncol. 40:328–330. 2018. View Article : Google Scholar : PubMed/NCBI
20	McFarlane J, Knight T, Sinha A, Cole T, Kiely N and Freeman R: Exostoses, enchondromatosis and metachondromatosis; diagnosis and management. Acta Orthop Belg. 82:102–105. 2016.PubMed/NCBI
21	Bowen ME, Boyden ED, Holm IA, Campos-Xavier B, Bonafé L, Superti-Furga A, Ikegawa S, Cormier-Daire V, Bovée JV, Pansuriya TC, et al: Loss-of-function mutations in PTPN11 cause metachondromatosis, but not Ollier disease or Maffucci syndrome. PLoS Genet. 7:e10020502011. View Article : Google Scholar : PubMed/NCBI
22	Siegfried A, Cances C, Denuelle M, Loukh N, Tauber M, Cavé H and Delisle MB: Noonan syndrome, PTPN11 mutations, and brain tumors. A clinical report and review of the literature. Am J Med Genet A. 173:1061–1065. 2017. View Article : Google Scholar : PubMed/NCBI
23	Rankin J, Short J, Turnpenny P, Castle B and Hanemann CO: Medulloblastoma in a patient with the PTPN11 p.Thr468Met mutation. Am J Med Genet A. 161A:2027–2029. 2013. View Article : Google Scholar : PubMed/NCBI
24	Roccograndi L, Binder ZA, Zhang L, Aceto N, Zhang Z, Bentires-Alj M, Nakano I, Dahmane N and O'Rourke DM: SHP2 regulates proliferation and tumorigenicity of glioma stem cells. J Neurooncol. 135:487–496. 2017. View Article : Google Scholar : PubMed/NCBI
25	Thiel C, Wilken M, Zenker M, Sticht H, Fahsold R, Gusek-Schneider GC and Rauch A: Independent NF1 and PTPN11 mutations in a family with neurofibromatosis-Noonan syndrome. Am J Med Genet A. 149A:1263–1267. 2009. View Article : Google Scholar : PubMed/NCBI
26	Nair S, Fort JA, Yachnis AT and Williams CA: Optic nerve pilomyxoid astrocytoma in a patient with Noonan syndrome. Pediatr Blood Cancer. 62:1084–1086. 2015. View Article : Google Scholar : PubMed/NCBI
27	Hu Z, Wang X, Fang H, Liu Y, Chen D, Zhang Q, Liu X, Wei D, Qu C and Wang S: A tyrosine phosphatase SHP2 gain-of-function mutation enhances malignancy of breast carcinoma. Oncotarget. 7:5664–5676. 2016.PubMed/NCBI
28	Beigbeder A, Chartier FJM and Bisson N: MPZL1 forms a signalling complex with GRB2 adaptor and PTPN11 phosphatase in HER2-positive breast cancer cells. Sci Rep. 7:115142017. View Article : Google Scholar : PubMed/NCBI
29	Zhang Q, Li Y, Zhao R, Wang X, Fan C, Xu Y, Liu Y, Li J and Wang S: The gain-of-function mutation E76K in SHP2 promotes CAC tumorigenesis and induces EMT via the Wnt/β-catenin signaling pathway. Mol Carcinog. 57:619–628. 2018. View Article : Google Scholar : PubMed/NCBI
30	Gagné-Sansfaçon J, Coulombe G, Langlois MJ, Langlois A, Paquet M, Carrier J, Feng GS, Qu CK and Rivard N: SHP-2 phosphatase contributes to KRAS-driven intestinal oncogenesis but prevents colitis-associated cancer development. Oncotarget. 7:65676–65695. 2016. View Article : Google Scholar : PubMed/NCBI
31	Zhang N, Liu H, Yue G, Zhang Y, You J and Wang H: Molecular Heterogeneity of Ewing Sarcoma as Detected by Ion Torrent Sequencing. PLoS One. 11:e01535462016. View Article : Google Scholar : PubMed/NCBI
32	Je EM, Choi YJ, Yoo NJ and Lee SH: Oncogenic PTPN11 mutations are rare in solid tumors. Pathol Oncol Res. 21:225–227. 2015. View Article : Google Scholar : PubMed/NCBI
33	Martinelli S, Carta C, Flex E, Binni F, Cordisco EL, Moretti S, Puxeddu E, Tonacchera M, Pinchera A, McDowell HP, et al: Activating PTPN11 mutations play a minor role in pediatric and adult solid tumors. Cancer Genet Cytogenet. 166:124–129. 2006. View Article : Google Scholar : PubMed/NCBI
34	Zhuo C, Shao M, Chen C, Lin C, Jiang D, Chen G, Tian H, Wang L, Li J and Lin X: Chemotherapy effectiveness and prognosis of gastric cancer influenced by PTPN11 polymorphisms. Cell Physiol Biochem. 39:1537–1552. 2016. View Article : Google Scholar : PubMed/NCBI
35	He C, Tu H, Sun L, Xu Q, Li P, Gong Y, Dong N and Yuan Y: Helicobacter pylori-related host gene polymorphisms associated with susceptibility of gastric carcinogenesis: A two-stage case-control study in Chinese. Carcinogenesis. 34:1450–1457. 2013. View Article : Google Scholar : PubMed/NCBI
36	Zhu F, Loh M, Hill J, Lee S, Koh KX, Lai KW, Salto-Tellez M, Iacopetta B, Yeoh KG and Soong R; Singapore Gastric Cancer Consortium, : Genetic factors associated with intestinal metaplasia in a high risk Singapore-Chinese population: A cohort study. BMC Gastroenterol. 9:762009. View Article : Google Scholar : PubMed/NCBI
37	Jiang J, Jia ZF, Kong F, Jin MS, Wang YP, Tian S, Suo J and Cao X: Association of polymorphism of PTPN 11 encoding SHP-2 with gastric atrophy but not gastric cancer in Helicobacter pylori seropositive Chinese population. BMC Gastroenterol. 12:892012. View Article : Google Scholar : PubMed/NCBI
38	Hishida A, Matsuo K, Goto Y, Naito M, Wakai K, Tajima K and Hamajima N: Associations of a PTPN11 G/A polymorphism at intron 3 with Helicobactor pylori seropositivity, gastric atrophy and gastric cancer in Japanese. BMC Gastroenterol. 9:512009. View Article : Google Scholar : PubMed/NCBI
39	Sapari NS, Loh M, Vaithilingam A and Soong R: Clinical potential of DNA methylation in gastric cancer: A meta-analysis. PLoS One. 7:e362752012. View Article : Google Scholar : PubMed/NCBI
40	Li J, Chen C, Bi X, Zhou C, Huang T, Ni C, Yang P, Chen S, Ye M and Duan S: DNA methylation of CMTM3, SSTR2, and MDFI genes in colorectal cancer. Gene. 630:1–7. 2017. View Article : Google Scholar : PubMed/NCBI
41	Kristensen LS, Mikeska T, Krypuy M and Dobrovic A: Sensitive Melting Analysis after Real Time-Methylation Specific PCR (SMART-MSP): High-throughput and probe-free quantitative DNA methylation detection. Nucleic Acids Res. 36:e422008. View Article : Google Scholar : PubMed/NCBI
42	Testino G, Testino R and Ancarani AO: Helicobacter pylori and gastric carcinogenesis. Recenti Prog Med. 92:573–577. 2001.(In Italian). PubMed/NCBI
43	Jiang J, Jin MS, Kong F, Wang YP, Jia ZF, Cao DH, Ma HX, Suo J and Cao XY: Increased expression of tyrosine phosphatase SHP-2 in Helicobacter pylori-infected gastric cancer. World J Gastroenterol. 19:575–580. 2013. View Article : Google Scholar : PubMed/NCBI
44	Fukushige S and Horii A: DNA methylation in cancer: A gene silencing mechanism and the clinical potential of its biomarkers. Tohoku J Exp Med. 229:173–185. 2013. View Article : Google Scholar : PubMed/NCBI
45	Li S, Hsu DD, Wang H and Feng GS: Dual faces of SH2-containing protein-tyrosine phosphatase Shp2/PTPN11 in tumorigenesis. Front Med. 6:275–279. 2012. View Article : Google Scholar : PubMed/NCBI
46	Bard-Chapeau EA, Li S, Ding J, Zhang SS, Zhu HH, Princen F, Fang DD, Han T, Bailly-Maitre B, Poli V, et al: Ptpn11/Shp2 acts as a tumor suppressor in hepatocellular carcinogenesis. Cancer Cell. 19:629–639. 2011. View Article : Google Scholar : PubMed/NCBI
47	Jiang C, Hu F, Tai Y, Du J, Mao B, Yuan Z, Wang Y and Wei L: The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma. J Cancer Res Clin Oncol. 138:637–646. 2012. View Article : Google Scholar : PubMed/NCBI
48	Xu R, Yu Y, Zheng S, Zhao X, Dong Q, He Z, Liang Y, Lu Q, Fang Y, Gan X, et al: Overexpression of Shp2 tyrosine phosphatase is implicated in leukemogenesis in adult human leukemia. Blood. 106:3142–3149. 2005. View Article : Google Scholar : PubMed/NCBI
49	Lucci MA, Orlandi R, Triulzi T, Tagliabue E, Balsari A and Villa-Moruzzi E: Expression profile of tyrosine phosphatases in HER2 breast cancer cells and tumors. Cell Oncol. 32:361–372. 2010.PubMed/NCBI
50	Hu ZQ, Ma R, Zhang CM, Li J, Li L, Hu ZT, Gao QI and Li WM: Expression and clinical significance of tyrosine phosphatase SHP2 in thyroid carcinoma. Oncol Lett. 10:1507–1512. 2015. View Article : Google Scholar : PubMed/NCBI
51	Cai P, Guo W, Yuan H, Li Q, Wang W, Sun Y, Li X and Gu Y: Expression and clinical significance of tyrosine phosphatase SHP-2 in colon cancer. Biomed Pharmacother. 68:285–290. 2014. View Article : Google Scholar : PubMed/NCBI
52	Luo X, Liao R, Hanley KL, Zhu HH, Malo KN, Hernandez C, Wei X, Varki NM, Alderson N, Chu C, et al: Dual Shp2 and Pten deficiencies promote non-alcoholic steatohepatitis and genesis of liver tumor-initiating cells. Cell Rep. 17:2979–2993. 2016. View Article : Google Scholar : PubMed/NCBI
53	Dong S, Li FQ, Zhang Q, Lv KZ, Yang HL, Gao Y and Yu JR: Expression and clinical significance of SHP2 in gastric cancer. J Int Med Res. 40:2083–2089. 2012. View Article : Google Scholar : PubMed/NCBI
54	Kim JS, Shin OR, Kim HK, Cho YS, An CH, Lim KW and Kim SS: Overexpression of protein phosphatase non-receptor type 11 (PTPN11) in gastric carcinomas. Dig Dis Sci. 55:1565–1569. 2010. View Article : Google Scholar : PubMed/NCBI
55	Tramacere I, Negri E, Pelucchi C, Bagnardi V, Rota M, Scotti L, Islami F, Corrao G, La Vecchia C and Boffetta P: A meta-analysis on alcohol drinking and gastric cancer risk. Ann Oncol. 23:28–36. 2012. View Article : Google Scholar : PubMed/NCBI
56	Wang D, Li C, Xu Y, Xing Y, Qu L, Guo Y, Zhang Y, Sun X and Suo J: Clinicopathological characteristics and prognosis of alpha-fetoprotein positive gastric cancer in Chinese patients. Int J Clin Exp Pathol. 8:6345–6355. 2015.PubMed/NCBI
57	Han T, Xiang DM, Sun W, Liu N, Sun HL, Wen W, Shen WF, Wang RY, Chen C, Wang X, et al: PTPN11/Shp2 overexpression enhances liver cancer progression and predicts poor prognosis of patients. J Hepatol. 63:651–660. 2015. View Article : Google Scholar : PubMed/NCBI
58	Chang W, Gao X, Han Y, Du Y, Liu Q, Wang L, Tan X, Zhang Q, Liu Y, Zhu Y, et al: Gene expression profiling-derived immunohistochemistry signature with high prognostic value in colorectal carcinoma. Gut. 63:1457–1467. 2014. View Article : Google Scholar : PubMed/NCBI
59	Chen SJ, Liu H, Liao CT, Huang PJ, Huang Y, Hsu A, Tang P, Chang YS, Chen HC and Yen TC: Ultra-deep targeted sequencing of advanced oral squamous cell carcinoma identifies a mutation-based prognostic gene signature. Oncotarget. 6:18066–18080. 2015.PubMed/NCBI